These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 28501762)

  • 41. First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience.
    Olsen IH; Langer SW; Jepsen I; Assens M; Federspiel B; Hasselby JP; Hansen CP; Kjaer A; Knigge U
    Acta Oncol; 2012 Jan; 51(1):97-100. PubMed ID: 21615243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
    Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
    Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
    Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
    World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.
    Elvebakken H; Venizelos A; Perren A; Couvelard A; Lothe IMB; Hjortland GO; Myklebust TÅ; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Knappskog S; Sorbye H
    Br J Cancer; 2024 Sep; 131(4):676-684. PubMed ID: 38909137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients.
    Huang YC; Yang NN; Chen HC; Huang YL; Yan WT; Yang RX; Li N; Zhang S; Yang PP; Feng ZZ
    World J Gastroenterol; 2021 Feb; 27(7):624-640. PubMed ID: 33642833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
    Brixi-Benmansour H; Jouve JL; Mitry E; Bonnetain F; Landi B; Hentic O; Bedenne L; Cadiot G
    Dig Liver Dis; 2011 Nov; 43(11):912-6. PubMed ID: 21831734
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants.
    Matsui K; Jin XM; Kitagawa M; Miwa A
    Arch Pathol Lab Med; 1998 Nov; 122(11):1010-7. PubMed ID: 9822131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.
    Basturk O; Tang L; Hruban RH; Adsay V; Yang Z; Krasinskas AM; Vakiani E; La Rosa S; Jang KT; Frankel WL; Liu X; Zhang L; Giordano TJ; Bellizzi AM; Chen JH; Shi C; Allen P; Reidy DL; Wolfgang CL; Saka B; Rezaee N; Deshpande V; Klimstra DS
    Am J Surg Pathol; 2014 Apr; 38(4):437-47. PubMed ID: 24503751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastroenteropancreatic high-grade neuroendocrine carcinoma.
    Sorbye H; Strosberg J; Baudin E; Klimstra DS; Yao JC
    Cancer; 2014 Sep; 120(18):2814-23. PubMed ID: 24771552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
    Hadoux J; Walter T; Kanaan C; Hescot S; Hautefeuille V; Perrier M; Tauveron I; Laboureau S; Do Cao C; Petorin C; Blanchet O; Faron M; Leteurtre E; Rousselet MC; Joubert Zakeyh J; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Lombard-Bohas C; Ducreux M; Scoazec JY; Baudin E; ;
    Endocr Relat Cancer; 2022 Oct; 29(10):569-580. PubMed ID: 35920609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
    Abdel-Rahman O; Koski SL
    Neuroendocrinology; 2022; 112(8):777-783. PubMed ID: 34649258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
    Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Iwasaki T; Takenaga N; Kasahara Y; Ouchi K; Shirota H; Takahashi M; Ishioka C
    Oncology; 2024; 102(5):359-367. PubMed ID: 37903486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
    Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
    BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis.
    Milione M; Maisonneuve P; Pellegrinelli A; Grillo F; Albarello L; Spaggiari P; Vanoli A; Tagliabue G; Pisa E; Messerini L; Centonze G; Inzani F; Scarpa A; Papotti M; Volante M; Sessa F; Fazio N; Pruneri G; Rindi G; Solcia E; La Rosa S; Capella C
    Endocr Relat Cancer; 2018 May; 25(5):583-593. PubMed ID: 29592868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas.
    Koumarianou A; Chatzellis E; Boutzios G; Tsavaris N; Kaltsas G
    Endokrynol Pol; 2013; 64(1):60-72. PubMed ID: 23450449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience.
    Bardasi C; Spallanzani A; Benatti S; Spada F; Laffi A; Antonuzzo L; Lavacchi D; Marconcini R; Ferrari M; Rimini M; Caputo F; Santini C; Cerma K; Casadei-Gardini A; Andrikou K; Salati M; Bertolini F; Fontana A; Dominici M; Luppi G; Gelsomino F
    Endocrine; 2021 Dec; 74(3):707-713. PubMed ID: 34231124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
    Araki T; Takashima A; Hamaguchi T; Honma Y; Iwasa S; Okita N; Kato K; Yamada Y; Hashimoto H; Taniguchi H; Kushima R; Nakao K; Boku N; Shimada Y
    Anticancer Drugs; 2016 Sep; 27(8):794-9. PubMed ID: 27341105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemotherapy for gastro-enteropancreatic endocrine tumours.
    O'Toole D; Hentic O; Corcos O; Ruszniewski P
    Neuroendocrinology; 2004; 80 Suppl 1():79-84. PubMed ID: 15477723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.